• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Consumer Cyclical·7506.T
Share

HOUSE OF ROSE Co.,Ltd. Stocks

¥ 1390Last Updated 27.07.2026

Issuer Rating

3/7
Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

¥ 39.99M

¥ 1390
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Headquartered in Tokyo, Japan, HOUSE OF ROSE Co.,Ltd. operates a chain of cosmetic retail stores throughout the country. These outlets offer an extensive selection of products, encompassing skincare, makeup, body and hair care essentials, bath items, fragranced body cosmetics, and subtly scented sundry goods, among other beauty supplies. In addition to its core cosmetic business, the company manages relaxation salons and operates fitness centers specifically for women under the Curves brand. By March 31, 2022, the firm had established a network of 248 locations in total, including 204 HOUSE OF ROSE stores, 21 Curves facilities, 17 relaxation salons, and 6 other retail establishments. The company itself was founded in 1978.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.07.2026 09:00

Rivian is benefiting from the growth of robotaxis. One analyst expects the stock to rise 26%.

28.07.2026 08:00

Germany will cut spending on ammunition. Which company will be negatively affected by this?

28.07.2026 07:30

An investor featured in *The Big Short* has reduced his stake in Google. He does not rule out a market correction.

28.07.2026 07:00

Hedge funds have increased their exposure to healthcare stocks to a nearly five-year high

28.07.2026 03:05

Amazon plans to deploy 5,000 satellites into orbit to compete with Starlink

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026